Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $63.40.

ELVN has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho lifted their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Stifel Nicolaus initiated coverage on Enliven Therapeutics in a report on Tuesday, June 9th. They issued a “buy” rating and a $60.00 price objective for the company. The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th.

Enliven Therapeutics Trading Up 2.8%

Shares of NASDAQ:ELVN opened at $49.12 on Friday. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $50.56. The company has a 50-day moving average price of $42.05 and a 200 day moving average price of $32.34. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -29.41 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, equities analysts forecast that Enliven Therapeutics will post -1.71 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the transaction, the director owned 51,884 shares in the company, valued at $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. The trade was a 10.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighVista Strategies LLC boosted its stake in Enliven Therapeutics by 83.1% during the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after purchasing an additional 117,619 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Enliven Therapeutics during the 3rd quarter worth $334,000. Seven Fleet Capital Management LP acquired a new stake in Enliven Therapeutics during the 4th quarter worth $180,000. Baker BROS. Advisors LP boosted its stake in Enliven Therapeutics by 136.3% during the 4th quarter. Baker BROS. Advisors LP now owns 271,406 shares of the company’s stock worth $4,180,000 after purchasing an additional 156,573 shares during the last quarter. Finally, Spruce Street Capital LP acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $6,870,000. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.